The Pharma Data

JULY 29, 2021

are living with spasticity across a variety of neurologic conditions — BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity. Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. million adults in the U.S.

Botox 52

Botox FDA Approval Doctors Doctor 52

The Pharma Data

SEPTEMBER 10, 2021

” Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA ® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX ® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.

Botox 52

Botox Doctors Doctor Medicine 52

The Pharma Data

SEPTEMBER 8, 2021

–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine –These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum.

Botox 52

Botox Doctors Doctor Medicine 52

XTalks

AUGUST 2, 2023

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 98

Sales Manufacturing FDA Approval Life Science 98